2'-Fucosyllactose

2′-Fucosyllactose (2′-FL)

1. Identity and Chemical Characterization

Names and Nomenclature

2′-Fucosyllactose (2′-FL) is a fucosylated neutral trisaccharide composed of L-fucose, D-galactose, and D-glucose units. Its systematic chemical name is α-L-fucopyranosyl-(1→2)-β-D-galactopyranosyl-(1→4)-D-glucopyranose, and it is commonly abbreviated as 2′-FL. Structurally, 2′-FL consists of an L-fucose monomer in the α stereochemical configuration linked at the first carbon to a monomer of D-galactose in the β stereochemical configuration at the second carbon, which is in turn linked at the first carbon to a monomer of D-glucose (which may be in either the α or β configuration) at the fourth carbon.

In the structural shorthand used in glycobiology, it is written as β-L-Fuc-(1→2)-β-D-Gal-(1→4)-D-Glc. It is a member of the broader class of human milk oligosaccharides (HMOs), which are unconjugated complex glycans that are uniquely abundant in human breast milk.

Natural Occurrence and Concentration

2′-FL is the most prevalent human milk oligosaccharide (HMO) naturally present in human breast milk, making up about 30% of all HMOs. The concentration of HMOs ranges from approximately 20 mg/mL in colostrum to 5 to 15 mg/mL in mature milk; 2′-FL is the most abundant HMO in both colostrum and mature milk, with concentrations of 0.76 to 4.78 mg/mL.

2′-FL bears an epitope of the Secretor histo-blood group system; approximately 70–80% of all milk samples contain 2′-FL, since its synthesis depends on a fucosyltransferase that is not uniformly expressed. More specifically, the first comprehensive analysis of HMOs from human milk in approximately 400 lactating women from 10 countries found that 85% of human milk samples had detectable 2′-FL at concentrations of 0.06–4.65 g/L; a second study found similar results from 410 lactating women from 11 international cohorts, with 65–98% of human milk samples having 2′-FL with mean concentrations ranging from 0.702–3.440 g/L.

2′-FL is not present in bovine milk, which is the basis of conventional infant formula. This absence represents one of the primary compositional differences between human breast milk and standard infant formula.

Discovery and Isolation History

2′-FL was first discovered in the 1950s in human milk. The oligosaccharide's primary isolation technique has been in use since 1972. Knowledge of HMOs more broadly has grown over decades; HMOs have come a long way since their very early days of first being recognized in the 1930s.

Commercial Forms and Preparations

In recent years, production of biosynthesized HMOs has become scalable to industrial standards; as a result, infant formula fortified with 2′-FL, the most abundant HMO in human breast milk, is now commercially available.

The two principal manufacturing routes are:

• Microbial fermentation using engineered Escherichia coli: 2′-FL can be enzymatically produced by α1,2-fucosyltransferase, using GDP-l-fucose as donor and lactose as acceptor. Metabolic engineering strategies have been widely used for enhancement of GDP-l-fucose supply and microbial production of 2′-FL with high productivity. One major commercial supplier produces its 2′-FL ingredient by fermentation with a genetically engineered strain of Escherichia coli BL21(DE3).
• Fermentation using Corynebacterium glutamicum: Another commercially available form is produced by fermentation with a genetically modified strain (APC199) of Corynebacterium glutamicum ATCC 13032.

The commercial novel food ingredient is mainly composed of the human-identical milk oligosaccharide (HiMO) 2′-FL, but also contains d-lactose, l-fucose, fucosylgalactose, difucosyllactose, d-glucose, and d-galactose, and a small fraction of other related saccharides. The primary difference in the specifications for 2′-FL from different microbial sources is limited to the carbohydrate components, specifically the levels of difucosyllactose (DFL), lactose, fucose, 3-fucosyllactose, and related saccharides; these differences are not considered to be a safety concern, as they relate to innocuous and structurally related carbohydrate components.

Available commercial formats include powdered bulk forms for use in infant formula, capsules and sachets for adult dietary supplementation, and fortified functional foods such as protein bars and beverages.

2. Traditional and Historical Use

2′-Fucosyllactose itself has no record of traditional or historical use in herbal or folk medicine, as its existence and function were only elucidated through modern analytical techniques. The compound was not isolated, named, or consciously employed in any pre-modern therapeutic tradition. It was not part of any pharmacopeia, and no ancient or early-modern culture possessed the biochemical tools to identify or characterize it.

Its biological history is, however, uniquely ancient: 2′-FL has been consumed by breastfed human infants throughout the entirety of human evolutionary history as a natural component of breast milk. The presence of 2′-FL in human milk, at concentrations far exceeding those found in the milk of other mammals, reflects the co-evolutionary relationship between humans and their gut microbiota. The compound does not appear to serve a direct energy-yielding role in the infant; its functions are now understood to be predominantly biological signaling, microbiome shaping, and pathogen exclusion, all of which are discussed in later sections.

There is no traditional herbal, Ayurvedic, Traditional Chinese Medicine, or Unani record of 2′-FL as an isolated or intentionally used substance. Its current use as a supplement or formula additive is entirely a product of modern biotechnology and nutritional science, beginning in the early 21st century when scalable biosynthesis became feasible.

3. Key Constituents, Active Compounds, and Mechanisms of Action

Structural Basis of Bioactivity

2′-FL is itself the active compound; it is not an extract whose activity depends on a constellation of phytochemicals. Its bioactivity derives directly from its specific trisaccharide structure. The α(1→2) linkage between fucose and galactose — the same glycosidic bond that defines the Secretor blood group antigen H-type 1/2 — is the structural feature that confers most of its biological properties, particularly its anti-adhesive and receptor-mimicking actions.

Resistance to Digestion and Colonic Fermentation

In infants, 2′-FL is resistant to digestion and reaches the colon where it is partially fermented, behaving as soluble prebiotic fiber. This has been confirmed in simulated digestion models: 86.67% of 2′-FL remained intact after simulated digestion, demonstrating its resistance to digestion throughout the upper gastrointestinal tract. The α(1→2) glycosidic linkage can potentially be cleaved by brush border membrane vesicle (BBMV) enzymes; however, only limited degradation occurred, likely due to low substrate specificity and restricted enzyme accessibility, indicating that the majority of ingested 2′-FL reaches the large intestine intact.

Evidence also suggests that portions of small soluble milk glycans, including 2′-FL, are absorbed, thus raising the possibility of systemic biological effects. This systemic absorption is relevant to proposed effects on the brain, immune system, and other distant organ systems.

Prebiotic (Bifidogenic and Butyrogenic) Activity

HMOs primarily function as prebiotics, facilitating the growth of beneficial bacteria such as Bifidobacterium to maintain microbial homeostasis. Prebiotics such as 2′-FL promote the growth of saccharolytic bacteria that generate short-chain fatty acids (SCFAs), which activate host G-protein coupled receptors (GPCRs) such as FFAR2 and FFAR3. These pathways influence host lipid metabolism, glucose homeostasis, and immune modulation.

In anaerobic batch culture fermenters, Bifidobacterium and Eubacterium rectale–Clostridium coccoides counts, and short-chain fatty acids (SCFAs) including butyrate increased during fermentation with 2′-FL and some of the 2′-FL/probiotic combinations.

Immune Modulation

HMOs interact with lectins on immune and epithelial cells, influencing immune responses via pathways such as Toll-like receptors (TLRs). At the molecular level, 2′-FL alleviates intestinal inflammation through putative TLR4 antagonism and the microbiota-derived SCFAs, both of which converge to modulate the TLR4/p38 MAPK-dependent signaling axis.

Probiotics modulate microbial composition and function, which in turn affects intestinal homeostasis through multiple axes, including epithelial barrier reinforcement, SCFA production, and suppression of pathobionts; Bifidobacterium and Lactobacillus species have been shown to upregulate tight junction proteins (e.g., occludin and ZO-1), thereby enhancing gut barrier integrity and reducing microbial translocation.

Anti-Adhesive and Antimicrobial Mechanisms

Numerous intestinal pathogens employ the host oligosaccharide sequences found on the cell surface of enterocytes to adhere as the first step in the infection process. Because HMOs, such as 2′-FL, also have a carbohydrate structure, they can act as soluble receptor analogs and prevent the pathogen from infecting the host. 2′-FL has been shown to inhibit the adhesion or infectivity of microbes, namely Campylobacter jejuni, enteropathogenic Escherichia coli, rotavirus, and norovirus.

HMOs are glycans in human milk with structures analogous to histo-blood group antigens (HBGAs). HMOs have been shown to act as decoy receptors to prevent the attachment of multiple enteric pathogens to host cells. With respect to norovirus specifically, X-ray crystallography studies with several HuNoV genotypes have shown that 2′-FL, an α1–2-fucosylated HMO, binds to the protruding domain of the HuNoV capsid protein VP1 in a similar pocket as HBGAs; 2′-FL has also been found to block the binding of HuNoV virus-like particles to porcine gastric mucin and saliva that contains HBGAs.

2′-FL has been shown to bind cholera toxin, E. coli toxins, and Shiga toxins. Epidemiological data has shown that mothers who produce higher concentrations of 2′-FL in their milk have offspring who are more protected from diarrheal illness caused by campylobacter, caliciviruses, and stable toxin of enterotoxigenic E. coli.

Neurological and Gut-Brain Axis Effects

Animal studies showed that 2′-FL — but not free fucose alone — enhanced hippocampal long-term potentiation (LTP), and that vagotomy inhibited the effects of oral 2′-FL on LTP and associative learning paradigms. Taken together, the data show that dietary 2′-FL affects cognitive domains and improves learning and memory in rats, and this effect is dependent on vagus nerve integrity, suggesting the gut-brain axis plays a role in 2′-FL-mediated cognitive benefits.

At the molecular level, continuous administration of 2′-FL increased the expression of several molecules involved in the storage of newly acquired memories, such as postsynaptic density protein 95, phosphorylated calcium/calmodulin-dependent kinase II, and brain-derived neurotrophic factor (BDNF) in cortical and subcortical structures.

4. Scientific Evidence by Area of Use

4.1 Infant Growth and Gastrointestinal Tolerance

Clinical evidence (strong): Multiple randomized controlled trials (RCTs) have evaluated 2′-FL–supplemented infant formula relative to standard formula and breastfed reference groups.

One double-blind RCT tested a starter infant formula containing Limosilactobacillus reuteri DSM 17938 supplemented with 2′-FL. Healthy infants under 14 days old (n = 289) were randomly assigned to a bovine milk-based formula with L. reuteri at 1 × 10⁷ CFU/g (control group) or the same formula with added 1.0 g/L 2′-FL (experimental group) until 6 months of age; a non-randomized breastfed group (n = 60) served as reference; the primary endpoint was weight gain through 4 months of age. Research has shown that infant formula containing 2′-FL and lacto-N-neotetraose (LNnT) supported age-appropriate growth, lower rates of both morbidity and medication use.

Studies have demonstrated good GI tolerability in both term and preterm infants across formula types. The body of evidence on growth non-inferiority relative to standard formula is considered robust.

4.2 Gut Microbiota Composition (Infants)

Clinical evidence (moderate to strong): The addition of 2′-FL to a prebiotic-containing formula (GOS + FOS) strengthened its bifidogenic effect, further supporting its safety, tolerability, and positive impact on gut microbiota development.

After intervention in a randomized clinical trial, Actinobacteriota emerged as the predominant phylum in both the HMO (60.4%) and breast milk (46.6%) groups; Bifidobacterium and Escherichia-Shigella were identified as the two most abundant bacterial genera in both groups; the relative abundance of Bifidobacterium in the HMO formula-fed group after intervention was similar to that in the breastfed group (p > 0.05). This finding supports the hypothesis that 2′-FL can shift the microbiota of formula-fed infants toward a composition resembling that of breastfed infants, though study sizes in this area remain moderate.

Term infant formula supplemented with 2′-fucosyllactose and lacto-N-neotetraose shifts stool microbiota and metabolic signatures closer to that of breastfed infants.

4.3 Immune Function and Inflammatory Cytokines (Infants)

Clinical evidence (moderate): Infants fed a formula containing 2′-fucosyllactose have lower inflammatory cytokines in a randomized controlled trial, similar to those who are breastfed. This was reported by Goehring et al. (2016) in the Journal of Nutrition, and represents one of the more rigorously controlled immunological findings from infant formula trials.

Preclinical research has demonstrated that HMOs and specifically 2′-FL are more than a prebiotic and have multiple functions, including immune, gut, and cognition benefits. However, most of the detailed mechanistic immune data remains at the preclinical (animal and in vitro) level; clinical confirmation in infants is emerging but not yet comprehensively established across all proposed immune pathways.

4.4 Incidence of Infantile Colic and Atopic Dermatitis

Clinical evidence (preliminary to moderate): An open-label, prospective clinical trial examined the effects of HMOs on the incidence of infantile colic (IC) and atopic dermatitis (AD) in full-term infants who were breastfed, standard formula-fed, or fed formula supplemented with 2′-FL for 1 year; the trial enrolled 338 full-term infants from 2020 to 2024, with 113 in the breastfed group, 111 in the standard formula group, and 114 in the 2′-FL formula group; IC was diagnosed using ROME IV criteria and AD was assessed with PO-SCORAD.

As an open-label rather than double-blind trial, this study carries limitations in terms of bias control. The finding that the 2′-FL formula group showed colic rates comparable to the breastfed group is preliminary and requires confirmation in blinded RCTs.

4.5 Gut Microbiota Composition and Symptoms in Adults with Gastrointestinal Conditions

Clinical evidence (very preliminary — open-label pilot only): 2′-FL, a prebiotic human milk oligosaccharide considered bifidogenic and butyrogenic, has been assessed for prebiotic effects alone or in combination with probiotic strains in vitro on stool from healthy, IBS, and ulcerative colitis adult donors.

In a subsequent open-label pilot trial, the effect of a 2′-FL-containing nutritional formula was evaluated in twelve adults with IBS or ulcerative colitis; gastrointestinal quality of life index (GIQLI) total and gastrointestinal symptom domain scores, stool counts of Bifidobacterium and Faecalibacterium prausnitzii, and stool SCFAs including butyrate, increased after six weeks of intervention. Consumption of the 2′-FL-containing nutritional formula by adults with IBS or ulcerative colitis was associated with improvements in intra- and extra-intestinal symptoms, and bifidogenic and butyrogenic effects.

Limitation: This pilot trial involved only twelve participants and used an open-label design, precluding conclusions about efficacy. Results must be considered hypothesis-generating at this stage.

4.6 Gut Microbiota Modulation in Healthy Adults

Clinical evidence (moderate — randomized, double-blind, placebo-controlled): A parallel, double-blind, randomized, placebo-controlled HMO-supplementation study was conducted in 100 healthy adult volunteers, consuming chemically produced 2′-FL and/or lacto-N-neotetraose (LNnT) at various daily doses and mixes or placebo for 2 weeks.

Supplementation of 2′-FL and LNnT at daily doses up to 20 g was shown to be safe and well tolerated, as assessed using the gastrointestinal symptoms rating scale; 16S rRNA sequencing analysis showed that HMO supplementation specifically modified the adult gut microbiota with the primary impact being substantial increases in relative abundance of Actinobacteria and Bifidobacterium in particular, and a reduction in relative abundance of Firmicutes and Proteobacteria.

This study provided the first set of data on safety, tolerance, and impact of HMO on the adult gut microbiota, and collectively showed that supplementing the diet with HMO is a valuable strategy to shape the human gut microbiota and specifically promote the growth of beneficial bifidobacteria.

4.7 Cognitive Development

Evidence (animal studies and observational human data only — no clinical intervention trials yet established): Extensive research has indicated positive effects of 2′-FL on cognitive development in the brain, yet its molecular mechanisms have remained elusive.

An observational study found that human milk oligosaccharide 2′-fucosyllactose links feedings at 1 month to cognitive development at 24 months in infants of normal and overweight mothers. At the preclinical level, following long-term supplementation for 4 weeks, 2′-FL was found to enhance cognitive memory function in growing mice as assessed through Y-maze, novel object recognition, and water maze tests.

2′-FL is associated with improved cognition and changes in brain tissue microstructure in breastfed infants; however, the mechanisms behind these neuronal effects are largely unknown. HMOs have been linked to enhanced cognitive, motor, and language development in infants, influencing genes such as GABRB2, SLC1A7, GLRA4, and CHRM3. These findings are primarily preclinical or correlational; controlled clinical intervention trials for cognitive outcomes are lacking.

4.8 Anti-Infective and Anti-Adhesive Activity

Evidence (preclinical and epidemiological — no interventional clinical trials): HMOs have been shown to prevent pathogen adhesion to host epithelia for multiple enteric bacteria, such as Campylobacter jejuni, Clostridioides difficile, and Escherichia coli O157, as well as viruses, such as rotavirus, coxsackievirus A9, and SARS-CoV-2.

X-ray crystallography studies have shown that 2′-FL binds to the protruding domain of the human norovirus capsid protein VP1 in a similar pocket as HBGAs; 2′-FL has also been found to block the binding of HuNoV virus-like particles to porcine gastric mucin and saliva that contains HBGAs, suggesting that 2′-FL can potentially act as a decoy receptor for human noroviruses.

The anti-adhesive data is compelling from a mechanistic standpoint, but controlled clinical intervention trials specifically testing 2′-FL to prevent infections in humans are not yet available; the evidence remains largely in vitro and animal-based.

4.9 Aging-Related Metabolic Disorders

Evidence (animal studies only — highly preliminary): One animal study validated the hypothesis that 2′-FL could alleviate aging-related metabolic disorders by modulating the gut microbial profile–adaptive immunity axis; the alleviation of dysregulated metabolic indices, including lipid deposition, dyslipidemia, glucose intolerance, systemic inflammation, and gut barrier damage, was confirmed in natural aging mice after 2′-FL treatment. No clinical data in humans exists for this indication.

5. Body Systems and Health Areas Associated with 2′-FL

• Gastrointestinal system: Prebiotic modulation of the gut microbiome; bifidogenic and butyrogenic effects; improvement of gut barrier integrity; potential benefits in IBS and ulcerative colitis (preliminary data only).
• Immune system: Modulation of inflammatory cytokines; TLR4 pathway antagonism; maturation of mucosal immunity in infants; anti-adhesive activity against enteric pathogens and toxins.
• Central nervous system / cognitive function: Preclinical evidence of effects on hippocampal LTP and memory via gut-brain axis; observational association with cognitive development at 24 months in infants.
• Metabolic system: Preclinical evidence in aged mice of effects on lipid deposition, glucose tolerance, and systemic inflammation via microbiome-T cell axis.
• Neonatal and infant health: Age-appropriate growth support; stool microbiota shift toward breastfed pattern; reduced inflammatory cytokines; potential reduction in colic and atopic dermatitis.

6. Dosage Forms and Reported Dosages

All dosages listed below are those reported in specific identified studies; they are not recommendations.

• Infant formula supplementation: One RCT used 1.0 g/L of 2′-FL added to infant formula, fed to infants until 6 months of age.
• Adult healthy volunteers (safety and microbiota study): A double-blind, randomized, placebo-controlled study in 100 healthy adult volunteers tested 2′-FL and/or LNnT at various daily doses and mixes for 2 weeks; doses up to 20 g/day were shown to be safe and well tolerated.
• Infant food supplement: One application proposed use of 2′-FL in food supplements for infants at the use level of 1.2 g/day; the resulting estimated intake in infants from this proposed use is within the natural intake of 2′-FL in breastfed infants.
• Natural intake in breastfed infants: Naturally occurring concentrations of 2′-FL in human milk range from 0.76 to 4.78 mg/mL, translating to total daily intakes in the range of several hundred milligrams to several grams, depending on the volume of milk consumed and maternal secretor status.

Dosages used in adult dietary supplements are not yet standardized, and population-wide intake recommendations from government or regulatory bodies have not been formally established for 2′-FL outside the infant formula context.

7. Safety Considerations

Regulatory Status

2′-FL produced by fermentation using genetically modified E. coli BL21(DE3) is permitted for use in infant formula, follow-on formula, and other products in the USA through the Generally Recognized as Safe (GRAS) scheme (FDA, 2015; 2021; 2022), and in Australia and New Zealand. Extensions of use of 2′-FL produced by genetically modified strains of E. coli K-12 (DH1), alone or in mixture with lacto-N-neotetraose (LNnT) or lacto-N-tetraose (LNT), to food supplements for infants were reviewed by EFSA and received positive opinions. Its use as an ingredient in infant formula did not raise any concern in Canada (Health Canada, 2018).

Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) delivered an opinion on the safety of 2′-FL as a novel food under Regulation (EU) 2015/2283; the novel food is already authorised as an ingredient in several food categories, including infant formula (IF) and follow-on formula (FOF).

Genotoxicity and Subchronic Toxicity

Toxicology studies of 2′-FL show no adverse, genotoxic or mutagenic effects, even at extremely high supraphysiological doses. The information provided on the potential mutagenicity of 2′-FL does not raise safety concerns regarding the genotoxicity of this novel food ingredient; based on observations from a sub-chronic 90-day toxicity study in rats, the EFSA Panel considers that the no-observed-adverse-effect-level (NOAEL) is 2,000 mg/kg body weight per day.

In one subchronic study using a 2′-FL/difucosyllactose mixture, the test substance was administered to neonatal rats at doses up to 5,000 mg/kg body weight/day, once daily for 90 days, followed by a 4-week recovery period; a concurrent reference control group received 5,000 mg/kg bw/day of fructooligosaccharide; no evidence of genotoxicity was observed; in the absence of compound-related adverse effects, 5,000 mg/kg bw/day was established as the no-observed-adverse-effect level.

Clinical Tolerability

In clinical trials, 2′-FL and LNnT have been shown to be safe and well tolerated in infants and adults. All participants in one 100-subject adult study completed the study without premature discontinuation; supplementation at daily doses up to 20 g was shown to be safe and well tolerated, as assessed using the gastrointestinal symptoms rating scale.

Secretor Status and Inter-Individual Variability in Exposure

2′-FL bears an epitope of the Secretor histo-blood group system; approximately 70–80% of all milk samples contain 2′-FL, since its synthesis depends on a fucosyltransferase that is not uniformly expressed. The fact that some infants are not exposed to 2′-FL has helped researchers to retrospectively probe for biological activities of this glycan. This natural variation in exposure, rather than a safety concern, has served as an epidemiological tool.

Specifications and Contaminant Profile

The information provided on the identity, manufacturing process, composition, and specifications of commercially produced 2′-FL does not raise safety concerns according to EFSA review. Commercially produced 2′-FL is manufactured with specifications controlling residual host-organism DNA, endotoxin levels, heavy metals, protein contaminants, and related saccharide impurities (principally difucosyllactose, 3-fucosyllactose, and residual lactose), all within established limits as reviewed by regulatory bodies.

Notable Absence of Known Drug Interactions

No pharmacokinetic drug interactions with 2′-FL have been identified in the available peer-reviewed literature reviewed by EFSA or the FDA GRAS process. As a dietary carbohydrate that is not metabolized by host intestinal enzymes but rather by colonic microbiota, the primary interaction risk relates to changes in intestinal microbiota composition, which could theoretically affect the absorption of orally administered drugs that depend on microbial biotransformation; however, no specific clinical drug interactions have been documented.

References

• Wikipedia — 2′-Fucosyllactose
• Castanys-Muñoz E, Martín MJ, Prieto PA. 2′-fucosyllactose: an abundant, genetically determined soluble glycan present in human milk. Nutrition Reviews. 2013. PubMed PMID 24246032
• Reverri EJ et al. Review of the Clinical Experiences of Feeding Infants Formula Containing the Human Milk Oligosaccharide 2′-Fucosyllactose. Nutrients. 2018;10:1346. PMC6213476
• Quantifying 2′-FL and 3-FL in different food applications by HPLC with refractive index detection. Food Science & Nutrition. PMC7027475
• Strategies for Enhancing Microbial Production of 2′-Fucosyllactose. Journal of Agricultural and Food Chemistry. 2022.
• Ryan JJ et al. Impact of 2′-Fucosyllactose on Gut Microbiota Composition in Adults with Chronic Gastrointestinal Conditions. Nutrients. 2021. PMC7998190
• Elison E et al. Oral supplementation of healthy adults with 2′-O-fucosyllactose and lacto-N-neotetraose is well tolerated and shifts the intestinal microbiota. Gut. 2016. PMC5082288
• Lazarini T et al. Bifidogenic Effect of 2′-Fucosyllactose on the Gut Microbiome of Healthy Formula-Fed Infants: A Randomized Clinical Trial. Nutrients. 2025. PMC11944528
• Supplementation of 2′-Fucosyllactose in Formula-Fed Infants Has Potential Benefits to Reduce the Risks of Infantile Colic and Atopic Dermatitis. PMC12457806
• Safety and efficacy of a probiotic-containing infant formula supplemented with 2′-fucosyllactose: a double-blind randomized controlled trial. Nutrition Journal. 2022. PMC8862345
• Vázquez E et al. Dietary 2′-Fucosyllactose Enhances Operant Conditioning and Long-Term Potentiation via Gut-Brain Communication through the Vagus Nerve in Rodents. PMC5113009
• Influence of microbially fermented 2′-fucosyllactose on neuronal-like cell activity in an in vitro co-culture system. PMC10881714
• 2′-Fucosyllactose inhibits human norovirus replication in human intestinal enteroids. Journal of Virology. 2024.
• Immunomodulatory and Prebiotic Effects of 2′-Fucosyllactose in Suckling Rats. Frontiers in Immunology. 2019.
• EFSA NDA Panel. Safety of 2′-O-fucosyllactose as a novel food ingredient. EFSA Journal. 2015.
• EFSA NDA Panel. Safety of the extension of use of 2′-fucosyllactose as a novel food pursuant to Regulation (EU) 2015/2283. PMC10632945
• EFSA NDA Panel. Safety of 2′-fucosyllactose produced by E. coli SGR5 as a Novel Food pursuant to Regulation (EU) 2015/2283. PMC10644224
• EFSA NDA Panel. Safety of 2′-fucosyllactose produced by C. glutamicum APC199 as a novel food pursuant to Regulation (EU) 2015/2283. PMC9749449
• EFSA NDA Panel. Safety of 2′-fucosyllactose/difucosyllactose mixture as a novel food pursuant to Regulation (EU) 2015/2283. PMC7009083
• Phipps KR et al. Safety evaluation of a mixture of the human-identical milk oligosaccharides 2′-fucosyllactose and difucosyllactose. Food and Chemical Toxicology. 2018. PubMed PMID 30076915
• UK Food Standards Agency. Assessment of Novel Food 2′-Fucosyllactose (2′-FL) for a Change to the Conditions of Use (RP2155). 2025.
• 2′-Fucosyllactose Inhibits Human Norovirus Replication in Human Intestinal Enteroids. PMC11160698
• Cognitive and behavioral benefits of 2′-fucosyllactose in growing mice: the roles of 5-hydroxytryptophan and gut microbiota. Microbiome. 2025.
• 2′-Fucosyllactose attenuates aging-related metabolic disorders through modulating gut microbiome–T cell axis. PMC11709090
• 2′-Fucosyllactose Modulates the Intestinal Immune Response to Gut Microbiota and Buffers Experimental Colitis in Mice. PMC12152263
• Synbiotic modulation of adult gut microbiome by 2′-fucosyllactose and Bifidobacterium longum subsp. infantis EFEL8008. Microbiome Research Reports. 2025.
• Genotoxicity and neonatal subchronic toxicity assessment of a novel mixture of lacto-N-fucopentaose I and 2′-fucosyllactose. PubMed PMID 33000492